USFDA approves Alembic Pharma anticonvulsant drug Carbamazepine
Vadodara: Alembic Pharmaceuticals Limited announced that the US Food & Drug Administration (USFDA) has approved its Abbreviated New Drug Application (ANDA) for Carbamazepine Tablets USP, 200 mg.
True Trigeminal Neuralgia (also known as Classical Trigeminal Neuralgia) is a chronic pain condition that affects the trigeminal nerve, which carries sensation from the face to the brain. It's characterized by sudden, severe, electric shock-like facial pain that typically affects one side of the face.
Earlier, Medical Dialogues reported that the company also received final approval from the USFDA for its ANDA for Pantoprazole Sodium for Injection, 40 mg/vial, intended for the treatment of pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults.
Read also: Alembic Pharma bags USFDA final approval for Pantoprazole Sodium for Injection for GERD
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.